Moderna's RSV shot 83.7% effective, late-stage trial shows

Moderna's respiratory syncytial virus vaccine candidate for older adults is about 84 percent effective, its phase 3 study showed, and the company said it will seek approval this year. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive